| BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies JM Bogenberger, SM Kornblau, WE Pierceall, R Lena, D Chow, CX Shi, ... Leukemia 28 (8), 1657-1665, 2014 | 206 | 2014 |
| Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies JM Bogenberger, D Delman, N Hansen, R Valdez, V Fauble, RA Mesa, ... Leukemia & lymphoma 56 (1), 226-229, 2015 | 152 | 2015 |
| Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations BH Durham, B Getta, S Dietrich, J Taylor, H Won, JM Bogenberger, ... Blood, The Journal of the American Society of Hematology 130 (14), 1644-1648, 2017 | 106 | 2017 |
| RNAi screening of the kinome with cytarabine in leukemias R Tibes, JM Bogenberger, L Chaudhuri, RT Hagelstrom, D Chow, ... Blood, The Journal of the American Society of Hematology 119 (12), 2863-2872, 2012 | 89 | 2012 |
| CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo L Chaudhuri, ND Vincelette, BD Koh, RM Naylor, KS Flatten, KL Peterson, ... Haematologica 99 (4), 688, 2014 | 88 | 2014 |
| Combined venetoclax and alvocidib in acute myeloid leukemia J Bogenberger, C Whatcott, N Hansen, D Delman, CX Shi, W Kim, ... Oncotarget 8 (63), 107206, 2017 | 76 | 2017 |
| Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents BZ Carter, PY Mak, DH Mak, Y Shi, Y Qiu, JM Bogenberger, H Mu, ... Journal of the National Cancer Institute 106 (2), djt440, 2014 | 76 | 2014 |
| The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia R Tibes, A Al-Kali, GR Oliver, DH Delman, N Hansen, K Bhagavatula, ... Journal of hematology & oncology 8, 1-10, 2015 | 57 | 2015 |
| Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias R Tibes, KT McDonagh, L Lekakis, JM Bogenberger, S Kim, N Frazer, ... Investigational new drugs 33, 389-396, 2015 | 41 | 2015 |
| Transcriptional silencing of MCL-1 through cyclin-dependent kinase inhibition in acute myeloid leukemia R Tibes, JM Bogenberger Frontiers in Oncology 9, 1205, 2019 | 38 | 2019 |
| Human T lymphotropic virus type 1 protein tax reduces histone levels JM Bogenberger, PJ Laybourn Retrovirology 5, 1-14, 2008 | 37 | 2008 |
| Targeting apoptosis in acute myeloid leukemia: Current status and future directions of BCL-2 inhibition with venetoclax and beyond JH Choi, JM Bogenberger, R Tibes Targeted Oncology 15 (2), 147-162, 2020 | 34 | 2020 |
| Emerging role of precision medicine in biliary tract cancers JM Bogenberger, TT DeLeon, M Arora, DH Ahn, MJ Borad NPJ precision oncology 2 (1), 21, 2018 | 29 | 2018 |
| Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma TT DeLeon, DH Ahn, JM Bogenberger, PZ Anastasiadis, M Arora, ... Future Oncology 14 (6), 553-566, 2018 | 27 | 2018 |
| JAK2 inhibitors in the treatment of myeloproliferative neoplasms R Tibes, JM Bogenberger, HL Geyer, RA Mesa Expert Opinion on Investigational Drugs 21 (12), 1755-1774, 2012 | 23 | 2012 |
| Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer M Arora, JM Bogenberger, A Abdelrahman, JL Leiting, X Chen, JB Egan, ... Cancer chemotherapy and pharmacology 85, 1063-1078, 2020 | 17 | 2020 |
| Phase I/IB study of azacitidine and hedgehog pathway inhibition with sonidegib (LDE225) in myeloid malignancies R Tibes, HE Kosiorek, A Dueck, J Palmer, JL Slack, EA Knight, ... Blood 130, 2629, 2017 | 17 | 2017 |
| Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms R Tibes, JM Bogenberger, KL Benson, RA Mesa Molecular diagnosis & therapy 16, 269-283, 2012 | 17 | 2012 |
| Advances in the treatment of biliary tract cancers PLSU Junior, J Bogenberger, MJ Borad Current Opinion in Gastroenterology 36 (2), 85-89, 2020 | 12 | 2020 |
| Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy PLS Uson Junior, U Majeed, J Yin, G Botrus, MB Sonbol, DH Ahn, ... JCO Precision Oncology 6 (1), e2100274, 2022 | 11 | 2022 |
Mitesh J. BoradMayo ClinicVerified email at mayo.edu
